Home / Auditor changes / Damora Therapeutics, Inc.
Filed 2026-04-20 路 Form 8-K 路 Accession 0001193125-26-163909 small
Price before filing: $26.6 (2026-04-17 close, split/dividend-adjusted)
Market cap at flag: $907.5M (2026-04-20) 路 Latest: $1.13B (2026-10-16)
| Window | DMRA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -9.2% | +4.4% | -13.6% | 2026-05-20 |
| 90 days | +24.0% | +4.8% | +19.3% | 2026-07-20 |
| 180 days | pending | pending | until 2026-10-17 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"A copy of EY Denmark's letter to the SEC dated April 17, 2026 regarding these statements is filed as Exhibit 16.1 to this Current Report on Form 8-K. (b) Appointment of New Independent Registered Public Accounting Firm On April 17, 2026, the Audit Committee engaged Ernst & Young LLP ("EY US") as the Company's independent registered public accounting firm, effective immediately."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: dismissed
Disagreements reported: no
New auditor: Ernst & Young LLP
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.